Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Partner

Alex Apostolopoulos

Goodwin Procter

main

Apostolopoulos Alex

Goodwin Counsel Alex Apostolopoulos, from New York, practices in in the firm's Tax group. Learn more about Alex's experience and recent cases today.

Alex Apostolopoulos

Areas of Practice

Credentials

Education

JD2011

BA2007

Admissions

Bars

Related Content

Goodwin Represents Mirion Technologies in $85.6 Million Debut Secondary Offering

Nutrabolt and Keurig Dr Pepper Announce Strategic Partnership

Biocon Biologics Completes $3.335 Billion Acquisition of Viatris’ Global Biosimilars Business

PTC To Acquire Leading SaaS Field Service Management Provider ServiceMax for $1.46 Billion

Ritchie Bros. To Acquire IAA, Inc. for $7.3 Billion

Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes

Biocon Biologics to Acquire Viatris’ Biosimilars Assets For up to $3.335 Billion

Cast & Crew Signs Definitive Agreement To Acquire Backstage Holdings

Tax

Secondaries